Naama Turner1, Andrew H Kaye2,3, Iddo Paldor4,5. 1. The Neurosurgery Department, Rambam (Maimonides) Medical Center, 2 Ha'aliya Street, 3109601, Haifa, Israel. naama.turner@mail.huji.ac.il. 2. The Neurosurgery Department, Hadassah Hebrew University Medical Center, Jerusalem, Israel. 3. Department of Surgery, University of Melbourne, Parkville, Australia. 4. The Neurosurgery Department, Rambam (Maimonides) Medical Center, 2 Ha'aliya Street, 3109601, Haifa, Israel. 5. The Technion - Israeli Institute of Technology, Haifa, Israel.
Abstract
PURPOSE: Meningiomas are a common tumor within the cranial cavity. They may be a target for metastatic spread of cancer elsewhere in the body. We analyzed all the data in the literature about tumor-to-meningioma metastasis (TTMM). METHODS: We performed a meta-analysis using the PRISMA checklist to locate all cases of TTMM in the PubMed and Medline databases. We collected patient and cancer parameters, meningioma parameters, and clinical factors. RESULTS: We located 124 articles, describing 152 cases of patients with TTMM. The mean (± SD) age of all patients was 62.21 ± 10.8 years, with even distribution above and below the mean. Of the cases, 65.9% were reported in women. The most common cancer origins of TTMM were breast and lung carcinoma, followed by kidney, prostate, and GI tract carcinoma. Cancer status is not a good marker of TTMM when managing a meningioma. In 36.69% of cases, TTMM was the presentation of an unknown cancer. In nearly 60% of the known cases, cancer was considered in remission for at least 1 year. Meningioma parameters are unhelpful when considering a TTMM. The distribution of meningioma location is similar to other series of meningioma reported in the literature. Meningioma grade is similar to meningiomas without TTMM. In 57.89%, the patient presented with a focal deficit. Presenting factors were seizures, elevated ICP, and others. Over 95% of cases were symptomatic at presentation. CONCLUSION: TTMM should be suspected in cases of meningioma in a patient with background cancer, regardless of meningioma parameters or cancer status.
PURPOSE:Meningiomas are a common tumor within the cranial cavity. They may be a target for metastatic spread of cancer elsewhere in the body. We analyzed all the data in the literature about tumor-to-meningioma metastasis (TTMM). METHODS: We performed a meta-analysis using the PRISMA checklist to locate all cases of TTMM in the PubMed and Medline databases. We collected patient and cancer parameters, meningioma parameters, and clinical factors. RESULTS: We located 124 articles, describing 152 cases of patients with TTMM. The mean (± SD) age of all patients was 62.21 ± 10.8 years, with even distribution above and below the mean. Of the cases, 65.9% were reported in women. The most common cancer origins of TTMM were breast and lung carcinoma, followed by kidney, prostate, and GI tract carcinoma. Cancer status is not a good marker of TTMM when managing a meningioma. In 36.69% of cases, TTMM was the presentation of an unknown cancer. In nearly 60% of the known cases, cancer was considered in remission for at least 1 year. Meningioma parameters are unhelpful when considering a TTMM. The distribution of meningioma location is similar to other series of meningioma reported in the literature. Meningioma grade is similar to meningiomas without TTMM. In 57.89%, the patient presented with a focal deficit. Presenting factors were seizures, elevated ICP, and others. Over 95% of cases were symptomatic at presentation. CONCLUSION: TTMM should be suspected in cases of meningioma in a patient with background cancer, regardless of meningioma parameters or cancer status.
Authors: Alim Emre Başaran; Barbara Kiesel; Josa M Frischer; Julia Furtner; Adelheid Wöhrer; Karin Dieckmann; Christian Dorfer Journal: World Neurosurg Date: 2019-09-03 Impact factor: 2.104
Authors: Roland Goldbrunner; Giuseppe Minniti; Matthias Preusser; Michael D Jenkinson; Kita Sallabanda; Emmanuel Houdart; Andreas von Deimling; Pantelis Stavrinou; Florence Lefranc; Morten Lund-Johansen; Elizabeth Cohen-Jonathan Moyal; Dieta Brandsma; Roger Henriksson; Riccardo Soffietti; Michael Weller Journal: Lancet Oncol Date: 2016-08-30 Impact factor: 41.316